

Inhibition of chloroplast translation as a new mode of action for herbicides


Kirill V. Sukhoverkov,^{1,2} Karen J. Breese,¹ Aleksandra W. Debowski,^{1,3} Monika W. Murcha,^{1,2} Keith A. Stubbs,^{1*} Joshua S. Mylne^{1,2,4*}

¹ School of Molecular Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Australia


² The ARC Centre of Excellence in Plant Energy Biology, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Australia

³ School of Biomedical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Australia

⁴ Centre for Crop and Disease Management, School of Molecular and Life Sciences, Curtin University, Bentley, WA 6102, Australia



Supporting Figure 1 | Linezolid **1**, similarly to the known chloroplast translation inhibitor lincomycin (linc) causes bleaching and root length reduction, only in photosynthesising plants, unlike ciprofloxacin (cip) that affects plants regardless of photosynthesis.




Supporting Figure 2 | Examples of cluster analysis of physicochemical properties of linezolid **1** and prepared analogues versus known herbicides. Charts were extracted from an interactive database containing the physicochemical properties of commercial herbicides. (A) polar surface area vs partition coefficient (logP); (B) polar surface area vs distribution coefficient (logD). Linezolid **1** is displayed as a black rhombus, blue dots represent the analogues prepared and the red dots represent the commercial herbicides.

General Experimental

All reagents and materials were purchased from commercial suppliers. Compounds **10** and **23** were purchased from SYNthesis Med Chem. Thin layer chromatography (TLC) was affected on Merck silica gel 60 F254 aluminium-backed plates and spots stained by heating with vanillin dip (6 g vanillin, 1 mL conc. H₂SO₄, 100 mL ethanol), unless stated otherwise. Flash column chromatography was performed on Merck silica gel using the specified solvents. NMR spectra were obtained on a Bruker Avance IIIHD 400, 500 or 600 spectrometers. The solvents used were CDCl₃ or DMSO-*d*₆ with CHCl₃ (¹H, δ 7.26 ppm), CDCl₃ (¹³C, δ 77.16 ppm), CD₃S(O)CD₂H (¹H, δ 2.50 ppm) or (CD₃)₂SO (¹³C, δ 39.52 ppm) used as an internal standard. Infrared spectra were obtained with neat samples on a PerkinElmer spectrum one FT-IR spectrometer fitted with a PerkinElmer Universal Attenuated Total Reflectance (ATR) sampling accessory. High resolution mass spectra (HR-MS) were obtained on a Waters LCT Premier XE TOF spectrometer, run in W-mode, using either the ESI or APCI equipped ion source, in positive or negative mode.

Preparation of *N*-acyl analogues




General Procedure A

To a stirred suspension of **10** or **23** (0.18 mmol, 1.0 equiv) in CH₂Cl₂ (1.5 mL) was added pyridine (0.36 mmol, 2.0 equiv) and the acid anhydride (0.36 mmol, 2.0 equiv). The mixture was stirred at r.t. for 18 h, then quenched with saturated aqueous NaHCO₃ (5 mL) and extracted with CH₂Cl₂ (3 x 5 mL), dried (MgSO₄), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/CH₂Cl₂) to yield the compound of interest.

General Procedure B


To a stirred suspension of **10** or **23** (0.18 mmol, 1.0 equiv) in CH₂Cl₂ (1.5 mL) was added pyridine (0.36 mmol, 2.0 equiv) and the acid chloride (0.36 mmol, 2.0 equiv). The mixture was stirred at r.t. for 2 h, then quenched with saturated aqueous NaHCO₃ (5 mL) and extracted with CH₂Cl₂ (3 x 5 mL), dried (MgSO₄), filtered and concentrated under reduced

pressure. The residue was purified by silica gel chromatography (0-3% MeOH/CH₂Cl₂) to yield the compound of interest.



N*-[[[(5*S*)-3-[3-fluoro-4-(formylamino)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **11*


A stirred solution of formic acid (90%, 0.065 mL, 1.7 mmol) and acetic anhydride (0.095 mL, 1.0 mmol) was stirred under N₂ at 70 °C for 1 h, then allowed to cool to r.t. At this time **10** (53 mg, 0.20 mmol) was then added and the resultant mixture heated at 50 °C for 0.5 h, then CH₂Cl₂ (1 mL) was added and heating was continued for 0.5 h. The residue was purified by silica gel chromatography (0-10% MeOH/CHCl₃), to yield the title compound **11** as a white powder (32 mg, 54%). R_f 0.30 (10% MeOH/CHCl₃); ¹H NMR (500 MHz, DMSO-*d*₆): major rotamer δ 10.08 (s, 1H), 8.28 (s, 1H), 8.24 (bt, 1H), 8.03 (dd, *J* = 8.9, 8.8 Hz), 7.60 (dd, *J* = 13.2, 2.0 Hz, 1H), 7.23 (dd, *J* = 8.8, 2.0 Hz, 1H), 4.75-4.70 (m, 1H), 4.10 (dd, *J* = 8.9, 8.8 Hz, 1H), 3.72 (dd, *J* = 8.8, 6.7 Hz, 1H), 3.42-3.40 (m, 2H), 1.83 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆): major rotamer δ 170.1, 159.9, 154.1, 152.6 (d, *J* = 243 Hz), 135.4 (d, *J* = 10 Hz), 123.3 (d, *J* = 3 Hz), 120.8 (d, *J* = 12 Hz), 113.5 (d, *J* = 3 Hz), 105.5 (d, *J* = 25 Hz), 71.7, 42.3, 41.4, 22.5; FTIR (ATR): ν 3297, 1724, 1680, 1651, 1528 cm⁻¹; HR-MS (ESI) *m/z*: found 296.1047; calculated for C₁₃H₁₅N₃O₄F [M+H]⁺ 296.1047.



(*S*)-*N*-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)acetamide **12**


The title compound was prepared according to General Procedure A to give **12** as an off white powder (51 mg, 92%). R_f 0.25 (5% MeOH/CHCl₃); ¹H NMR (600 MHz, DMSO-*d*₆): δ 9.69 (s, 1H), 8.24 (t, *J* = 5.7 Hz, 1H), 7.80 (dd, *J* = 8.8, 8.9 Hz, 1H), 7.56 (dd, *J* = 13.2, 2.2 Hz, 1H), 7.21 (dd, *J* = 8.8, 2.2 Hz, 1H), 4.74-4.70 (m, 1H), 4.10 (dd, *J* = 8.9, 8.9 Hz, 1H), 3.72 (dd, *J* = 8.9, 6.5 Hz, 1H), 3.41 (app t, *J* = 5.5 Hz, 2H), 2.06 (s, 3H), 1.83 (s, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆): δ 170.0, 168.6, 154.0, 153.6 (d, *J* = 244 Hz), 135.5 (d, *J* = 10 Hz), 124.8, 121.5 (d, *J* = 12 Hz), 113.3 (d, *J* = 3 Hz), 105.4 (d, *J* = 25 Hz), 71.6, 47.2, 41.4,

23.3, 22.4; FTIR (ATR): ν 3334, 1749, 1661, 1539 cm^{-1} ; HR-MS (ESI) m/z : found 310.1202; calculated for $\text{C}_{14}\text{H}_{17}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 310.1203.




(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)propanamide 13

The title compound was prepared according to General Procedure A to give **13** as a beige powder (54 mg, 94%). R_f 0.28 (5% MeOH/ CHCl_3); ^1H NMR (500 MHz, DMSO-d_6): δ 9.60 (s, 1H), 8.24 (t, $J = 5.8$ Hz, 1H), 7.80 (dd, $J = 8.9, 8.9$ Hz, 1H), 7.56 (dd, $J = 13.2, 2.4$ Hz, 1H), 7.22 (dd, $J = 8.9, 2.4$ Hz, 1H), 4.75-4.69 (m, 1H), 4.10 (dd, $J = 9.0, 9.0$ Hz, 1H), 3.72 (dd, $J = 9.0, 6.5$ Hz, 1H), 3.41 (app t, $J = 5.5$ Hz, 2H), 2.36 (q, $J = 7.5$ Hz, 2H), 1.83 (s, 3H), 1.07 (t, $J = 7.5$ Hz, 3H); ^{13}C NMR (126 MHz, DMSO-d_6): δ 172.3, 170.0, 154.0, 153.7 (d, $J = 244$ Hz), 135.5 (d, $J = 10$ Hz), 124.9, 121.5 (d, $J = 12$ Hz), 113.3 (d, $J = 3$ Hz), 105.4 (d, $J = 25$ Hz), 71.6, 47.2, 41.4, 28.8, 22.4, 9.6; FTIR (ATR): ν 3301, 1737, 1662, 1532 cm^{-1} ; HR-MS (ESI) m/z : found 324.1358; calculated for $\text{C}_{15}\text{H}_{19}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 324.1360.




(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)butanamide 14

The title compound was prepared according to General Procedure A to give **14** as an off-white powder (49 mg, 82%). R_f 0.30 (5% MeOH/ CHCl_3); ^1H NMR (500 MHz, DMSO-d_6): δ 9.61 (s, 1H), 8.24 (t, $J = 5.8$ Hz, 1H), 7.78 (dd, $J = 8.9, 8.9$ Hz, 1H), 7.56 (dd, $J = 13.2, 2.4$ Hz, 1H), 7.22 (dd, $J = 8.9, 2.4$ Hz, 1H), 4.75-4.70 (m, 1H), 4.10 (dd, $J = 9.1, 9.0$ Hz, 1H), 3.72 (dd, $J = 9.1, 6.5$ Hz, 1H), 3.41 (app t, $J = 5.5$ Hz, 2H), 2.32 (t, $J = 7.3$ Hz, 2H), 1.83 (s, 3H), 1.59 (tt, $J = 7.4, 7.3$ Hz, 2H), 0.91 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (126 MHz, DMSO-d_6): δ 171.4, 170.0, 154.0, 153.8 (d, $J = 244$ Hz), 135.6 (d, $J = 10$ Hz), 125.1, 121.5 (d, $J = 12$ Hz), 113.3 (d, $J = 3$ Hz), 105.4 (d, $J = 25$ Hz), 71.6, 47.2, 41.4, 37.5, 22.4, 18.6, 13.6; FTIR (ATR): ν 3268, 1727, 1660, 1532 cm^{-1} ; HR-MS (ESI) m/z : found; calculated for $\text{C}_{16}\text{H}_{21}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 338.1516.




(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)pentanamide 15

The title compound was prepared according to General Procedure A to give **15** as a white powder (38 mg, 60%). R_f 0.13 (5% MeOH/ CH₂Cl₂); ¹H NMR (600 MHz, DMSO-*d*₆): δ 9.61 (s, 1H), 8.24 (t, J = 5.8 Hz, 1H), 7.77 (dd, J = 9.0, 9.0 Hz, 1H), 7.55 (dd, J = 13.2, 2.4 Hz, 1H), 7.21 (dd, J = 9.0, 2.4 Hz, 1H), 4.74-4.70 (m, 1H), 4.10 (dd, J = 9.0, 9.0 Hz, 1H), 3.72 (dd, J = 9.0, 6.6 Hz, 1H), 3.41 (app t, 5.5 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 1.83 (s, 3H), 1.56 (tt, J = 7.5, 7.5 Hz, 2H), 1.32 (tq, J = 7.5, 7.5 Hz, 2H), 0.89 (t, J = 7.5 Hz, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆): δ 171.6, 170.0, 154.0, 153.8 (d, J = 244 Hz), 135.6 (d, J = 11 Hz), 125.1, 121.5 (d, J = 12 Hz), 113.3 (d, J = 3 Hz), 105.5 (d, J = 26 Hz), 71.6, 47.2, 41.4, 35.4, 27.3, 22.4, 21.8, 13.8; FTIR (ATR): ν 3289, 1727, 1659, 1532 cm⁻¹; HR-MS (ESI) m/z : found 374.1478; calculated for C₁₇H₂₂FN₃O₄Na [M+Na]⁺ 374.1492.




(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)hexanamide 16

The title compound was prepared according to General Procedure A to give **16** as a white powder (35 mg, 51%). R_f 0.13 (5% MeOH/ CH₂Cl₂); ¹H NMR (600 MHz, DMSO-*d*₆): δ 9.61 (s, 1H), 8.25 (t, J = 5.9 Hz, 1H), 7.77 (dd, J = 8.9, 8.9 Hz, 1H), 7.55 (dd, J = 13.1, 2.5 Hz, 1H), 7.21 (dd, J = 8.9, 2.5 Hz, 1H), 4.74-4.70 (m, 1H), 4.10 (dd, J = 9.0, 9.0 Hz, 1H), 3.72 (dd, J = 9.0, 6.6 Hz, 1H), 3.41 (app t, 5.5 Hz, 2H), 2.33 (t, J = 7.4 Hz, 2H), 1.83 (s, 3H), 1.58 (tt, J = 7.4, 7.3 Hz, 2H), 1.37-1.25 (m, 4H), 0.87 (t, J = 7.0 Hz, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆): δ 171.6, 170.0, 154.0, 153.8 (d, J = 243 Hz), 135.6 (d, J = 11 Hz), 125.0, 121.5 (d, J = 12 Hz), 113.3 (d, J = 3 Hz), 105.5 (d, J = 26 Hz), 71.6, 47.2, 41.4, 35.6, 30.9, 24.8, 22.4, 21.9, 13.9; FTIR (ATR): ν 3269, 1740, 1662, 1531 cm⁻¹; HR-MS (ESI) m/z : found 366.1819; calculated for C₁₈H₂₅FN₃O₄ [M+H]⁺ 366.1829.




(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)nonanamide 17

The title compound was prepared according to General Procedure B to give **17** as a white powder (49 mg, 67%). R_f 0.10 (5% MeOH/ CH₂Cl₂); ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.60 (s, 1H), 8.24 (t, J = 5.8 Hz, 1H), 7.77 (dd, J = 8.9, 8.9 Hz, 1H), 7.55 (dd, J = 13.2, 2.4 Hz, 1H), 7.21 (dd, J = 8.9, 2.4 Hz, 1H), 4.75-4.69 (m, 1H), 4.10 (dd, J = 9.0, 9.0 Hz, 1H), 3.72 (dd, J = 9.0, 6.4 Hz, 1H), 3.41 (app t, J = 5.5, 2H), 2.33 (t, J = 7.4 Hz, 2H), 1.83 (s, 3H), 1.57 (tt, J = 7.4, 7.0 Hz, 2H), 1.32-1.22 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃): δ 171.6, 170.0, 154.0, 153.8 (d, J = 243 Hz), 135.6 (d, J = 11 Hz), 125.0, 121.5 (d, J = 12 Hz), 113.3 (d, J = 3 Hz), 105.5 (d, J = 25 Hz), 71.6, 47.2, 41.4, 35.6, 31.3, 28.7, 28.6, 25.1, 22.4, 22.1, 14.0; FTIR (ATR): ν 3291, 1729, 1675, 1538 cm⁻¹; HR-MS (ESI) m/z : found 430.2117; calculated for C₂₁H₃₀FN₃O₄Na [M+Na]⁺ 430.2118.




(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)isobutyramide 18

The title compound was prepared according to General Procedure A to give **18** as a white powder (31 mg, 51%). R_f 0.13 (5% MeOH/ CH₂Cl₂); ¹H NMR (500 MHz, DMSO-*d*₆): δ 9.56 (s, 1H), 8.24 (t, J = 5.8 Hz, 1H), 7.75 (dd, J = 8.9, 8.9 Hz, 1H), 7.55 (dd, J = 13.2, 2.4 Hz, 1H), 7.21 (dd, J = 8.9, 2.4 Hz, 1H), 4.75-4.70 (m, 1H), 4.10 (dd, J = 9.0, 9.0 Hz, 1H), 3.73 (dd, J = 9.0, 6.5 Hz, 1H), 3.41 (app t, J = 5.5 Hz, 2H), 2.70 (sept, J = 7.0 Hz, 1H), 1.83 (s, 3H), 1.09 (d, J = 7.0 Hz, 6H); ¹³C NMR (126 MHz, DMSO-*d*₆): δ 175.5, 170.0, 154.0, 154.0 (d, J = 244 Hz), 135.7 (d, J = 10 Hz), 125.3, 121.5 (d, J = 13 Hz), 113.3 (d, J = 3 Hz), 105.4 (d, J = 25 Hz), 71.6, 47.2, 41.4, 34.2, 22.4, 19.5; FTIR (ATR): ν 3284, 1729, 1670, 1657, 1537 cm⁻¹; HR-MS (ESI) m/z : found 360.1342; calculated for C₁₆H₂₀FN₃O₄Na [M+Na]⁺ 360.1336.



(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-3-methylbutanamide 19


The title compound was prepared according to General Procedure A to give **19** as a white powder (38 mg, 60%). R_f 0.13 (5% MeOH/ CH_2Cl_2); ^1H NMR (500 MHz, DMSO-d_6): δ 9.60 (s, 1H), 8.24 (t, J = 5.6 Hz, 1H), 7.74 (dd, J = 8.8, 8.8 Hz, 1H), 7.56 (dd, J = 13.1, 2.2 Hz, 1H), 7.22 (dd, J = 8.8, 2.2 Hz, 1H), 4.75-4.70 (m, 1H), 4.10 (dd, J = 9.0, 9.0 Hz, 1H), 3.72 (dd, J = 9.0, 6.5 Hz, 1H), 3.41 (app t, J = 5.5 Hz, 2H), 2.22 (d, J = 7.0 Hz, 2H), 2.05 (dsept, J = 7.0, 6.5 Hz, 1H), 1.83 (s, 3H), 0.93 (d, J = 6.5 Hz, 6H); ^{13}C NMR (126 MHz, DMSO-d_6): δ 170.9, 170.0, 154.0, 154.0 (d, J = 244 Hz), 135.7 (d, J = 11 Hz), 125.3, 121.4 (d, J = 13 Hz), 113.3 (d, J = 3 Hz), 105.5 (d, J = 26 Hz), 71.6, 47.2, 44.8, 41.4, 25.7, 22.4, 22.3; FTIR (ATR): ν 3285, 1736, 1658, 1534 cm^{-1} ; HR-MS (ESI) m/z : found 374.1502; calculated for $\text{C}_{17}\text{H}_{22}\text{FN}_3\text{O}_4\text{Na}$ $[\text{M}+\text{Na}]^+$ 374.1516.



(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-2-ethylbutanamide 20


To a stirred suspension of **10** (48 mg, 0.18 mmol) in pyridine (1.5 mL), diethylacetic anhydride (0.21 mL, 0.90 mmol) was added. The mixture was stirred at r.t. for 18 h, then diluted with toluene (3 mL) and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/ CH_2Cl_2), and the resultant solid was triturated with CH_2Cl_2 (2 x 0.2 mL) to yield the title compound as a white powder (40 mg, 61%). R_f 0.13 (5% MeOH/ CH_2Cl_2); ^1H NMR (500 MHz, DMSO-d_6): δ 9.60 (s, 1H), 8.24 (t, J = 5.8, 1H), 7.68 (dd, J = 8.9, 8.9 Hz, 1H), 7.55 (dd, J = 13.0, 2.4 Hz, 1H), 7.23 (dd, J = 8.9, 2.4 Hz, 1H), 4.75-4.70 (m, 1H), 4.11 (dd, J = 9.0, 9.0 Hz, 1H), 3.73 (dd, J = 9.0, 7.7 Hz, 1H), 3.41 (app t, J = 5.5 Hz, 2H), 2.35-2.30 (m, 1H), 1.58-1.49 (m, 2H), 1.47-1.39 (m, 2H), 0.87

(t, $J = 7.4$ Hz, 3H); ^{13}C NMR (126 MHz, DMSO- d_6): δ 174.2, 170.0, 154.4 (d, $J = 244$ Hz), 154.0, 136.0 (d, $J = 10$ Hz), 125.9, 121.2 (d, $J = 13$ Hz), 113.3 (d, $J = 3$ Hz), 105.5 (d, $J = 26$ Hz), 71.6, 49.0, 47.3, 41.4, 25.3, 22.4, 11.8; FTIR (ATR): ν 3276, 1739, 1658, 1525 cm^{-1} ; HR-MS (ESI) m/z : found 388.1646; calculated for $\text{C}_{18}\text{H}_{24}\text{FN}_3\text{O}_4\text{Na}$ $[\text{M}+\text{Na}]^+$ 388.1649.



(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)benzamide 35


The title compound was prepared according to General Procedure B followed by recrystallisation from MeOH to give **35** as a white powder (23 mg, 34%). R_f 0.07 (5% MeOH/ CH_2Cl_2); ^1H NMR (500 MHz, DMSO- d_6): δ 10.09 (s, 1H), 8.26 (t, $J = 5.8$ Hz, 1H), 7.62-7.52 (m, 5H), 7.32 (dd, $J = 9.0, 2.5$ Hz, 1H), 4.77-4.72 (m, 1H), 4.15 (dd, $J = 9.0, 9.0$ Hz, 1H), 3.76 (dd, $J = 9.0, 6.5$ Hz, 1H), 3.43 (app t, $J = 5.5$ Hz, 2H), 1.84 (s, 3H); ^{13}C NMR (126 MHz, DMSO- d_6): δ 170.1, 165.5, 155.8 (d, $J = 245$ Hz), 154.1, 137.1 (d, $J = 11$ Hz), 133.8, 131.8, 128.5, 127.7, 127.7 (d, $J = 3$ Hz), 120.9 (d, $J = 13$ Hz), 113.4 (d, $J = 3$ Hz), 105.6 (d, $J = 25$ Hz), 71.7, 47.3, 41.4, 22.5; FTIR (ATR): ν 3288, 1731, 1653, 1515 cm^{-1} ; HR-MS (ESI) m/z : found 394.1188; calculated for $\text{C}_{19}\text{H}_{18}\text{FN}_3\text{O}_4\text{Na}$ $[\text{M}+\text{Na}]^+$ 394.1179.



N-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinecarboxamide 38


The title compound was prepared according to General Procedure B but instead using pyridine-2-carbonyl chloride hydrochloride (64 mg, 0.36 mmol) and pyridine (0.04 mL, 0.5 mmol) to give **38** as a white powder (31 mg, 46%). R_f 0.17 (5% MeOH/ CH_2Cl_2); ^1H NMR (600 MHz, DMSO- d_6): δ 10.37 (s, 1H), 8.75 (d, $J = 4.8$ Hz), 8.25 (t, $J = 5.8$ Hz, 1H), 8.16 (d, $J = 7.8$ Hz, 1H), 8.09 (ddd, $J = 7.8, 7.7, 1.6$ Hz), 8.04 (dd, $J = 8.9, 8.9$ Hz, 1H), 7.71 (ddd, $J = 7.7, 4.8, 1.1$ Hz, 1H), 7.66 (dd, $J = 13.2, 1.1$ Hz, 1H), 7.32 (dd, $J = 8.9, 1.1$ Hz, 1H),

4.77-4.73 (m, 1H), 4.14 (dd, $J = 8.9, 8.9$ Hz, 1H), 3.76 (dd, $J = 8.9, 6.5$ Hz, 1H), 3.43 (app t, $J = 5.5$ Hz, 2H), 1.84 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6): δ 170.0, 162.1, 154.0, 153.9 (d, $J = 244$ Hz), 149.0, 148.6, 138.3, 136.1 (d, $J = 11$ Hz), 127.3, 124.1, 122.2, 120.9 (d, $J = 11$ Hz), 113.6 (d, $J = 2$ Hz), 105.5 (d, $J = 25$ Hz), 71.7, 47.3, 41.4, 22.4; FTIR (ATR): ν 3276, 1744, 1674, 1654, 1526 cm^{-1} ; HR-MS (ESI) m/z : found 395.1138; calculated for $\text{C}_{18}\text{H}_{17}\text{FN}_4\text{O}_4\text{Na}$ $[\text{M}+\text{Na}]^+$ 395.1132.



N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-pyridinecarboxamide **39*


The title compound was prepared according to General Procedure B but instead using pyridine-4-carbonyl chloride hydrochloride (64 mg, 0.36 mmol) and pyridine (0.04 mL, 0.5 mmol) to give **39** as a white powder (21 mg, 31%). R_f 0.27 (10% MeOH/ CH_2Cl_2); ^1H NMR (600 MHz, DMSO- d_6): δ 10.41 (s, 1H), 8.79 (d, $J = 5.4$ Hz, 2H), 8.26 (t, $J = 5.7$ Hz, 1H), 7.87 (d, $J = 5.4$ Hz, 2H), 7.63-7.58 (m, 2H), 7.34 (dd, $J = 8.8, 1.9$ Hz, 1H), 4.77-4.73 (m, 1H), 4.15 (dd, $J = 9.0, 9.0$ Hz, 1H), 3.77 (dd, $J = 9.0, 6.5$ Hz, 1H), 3.43 (app t, $J = 5.5$ Hz, 2H), 1.84 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6): δ 170.1, 164.0, 155.7 (d, $J = 246$ Hz), 154.1, 150.4, 140.9, 137.5 (d, $J = 10$ Hz), 127.6, 121.6, 120.1 (d, $J = 13$ Hz), 113.4 (d, $J = 2$ Hz), 105.7 (d, $J = 26$ Hz), 71.7, 47.3, 41.4, 22.5; FTIR (ATR): ν 3277, 1729, 1655, 1532 cm^{-1} ; HR-MS (ESI) m/z : found 373.1320; calculated for $\text{C}_{18}\text{H}_{18}\text{FN}_4\text{O}_4$ $[\text{M}+\text{H}]^+$ 373.1312.



N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-thiophenecarboxamide **40*


The title compound was prepared according to General Procedure B followed by trituration with CH_2Cl_2 to give **40** as a white powder (18 mg, 26%). R_f 0.11 (5% MeOH/ CH_2Cl_2); ^1H

NMR (500 MHz, DMSO- d_6): δ 10.13 (bs, 1H), 8.25 (t, J = 5.8 Hz, 1H), 7.99 (dd, J = 3.7, 0.9 Hz, 1H), 7.86 (dd, J = 5.0, 0.9 Hz, 1H), 7.60 (dd, J = 12.8, 2.4 Hz, 1H), 7.55 (dd, J = 8.8, 8.8 Hz, 1H), 7.32 (dd, J = 8.8, 2.4 Hz, 1H), 7.22 (dd, J = 5.0, 3.7 Hz, 1H), 4.77-4.72 (m, 1H), 4.14 (dd, J = 9.0, 9.0 Hz, 1H), 3.76 (dd, J = 9.0, 6.5 Hz, 1H), 3.43 (app t, J = 5.5 Hz, 2H), 1.84 (s, 3H); ^{13}C NMR (126 MHz, DMSO- d_6 - d_6): δ 170.1, 160.1, 155.8 (d, J = 246 Hz), 154.1, 139.1, 137.3 (d, J = 10 Hz), 132.0, 129.5, 128.2, 127.8 (d, J = 3 Hz), 120.2 (d, J = 13 Hz), 113.4 (d, J = 3 Hz), 105.6 (d, J = 26 Hz), 71.7, 47.3, 41.4, 22.5; FTIR (ATR): ν 3335, 1756, 1672, 1525 cm^{-1} ; HR-MS (ESI) m/z : found 400.0736; calculated for $\text{C}_{17}\text{H}_{16}\text{FN}_3\text{O}_4\text{SNa}$ $[\text{M}+\text{Na}]^+$ 400.0743.




N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-thiophenecarboxamide **41*

The title compound was prepared according to General Procedure B to give **41** as a white powder (38 mg, 56%). R_f 0.11 (5% MeOH/ CH_2Cl_2); ^1H NMR (600 MHz, DMSO- d_6): δ 9.93 (s, 1H), 8.34 (dd, J = 2.9, 1.2 Hz, 1H), 8.26 (t, J = 5.9 Hz, 1H), 7.65 (dd, J = 5.0, 2.9 Hz, 1H), 7.61 (dd, J = 5.0, 1.2 Hz, 1H), 7.59 (dd, J = 12.8, 2.5 Hz, 1H), 7.55 (dd, J = 8.8, 8.8 Hz, 1H), 7.31 (dd, J = 8.8, 2.5 Hz, 1H), 4.76-4.72 (m, 1H), 4.14 (dd, J = 9.0, 9.0 Hz, 1H), 3.76 (dd, J = 9.0, 6.5 Hz, 1H), 3.43 (app t, J = 5.5 Hz, 2H), 1.84 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6): δ 170.1, 160.9, 155.8 (d, J = 245 Hz), 154.1, 137.1 (d, J = 10 Hz), 137.0, 130.1, 127.7 (d, J = 2 Hz), 127.1, 127.0, 120.6 (d, J = 12 Hz), 113.4 (d, J = 3 Hz), 105.6 (d, J = 26 Hz), 71.7, 47.3, 41.4, 22.5; FTIR (ATR): ν 3289, 1728, 1651, 1530 cm^{-1} ; HR-MS (ESI) m/z : found 400.0746; calculated for $\text{C}_{17}\text{H}_{16}\text{FN}_3\text{O}_4\text{SNa}$ $[\text{M}+\text{Na}]^+$ 400.0743.



N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-furancarboxamide **42*


The title compound was prepared according to General Procedure B but instead when the reaction was complete the mixture was filtered, and the solid was washed with CH₂Cl₂ (2 x 1 mL) and MeOH (1 mL) to give **42** as a white powder (42 mg, 65%). *R*_f 0.16 (5% MeOH/CH₂Cl₂); ¹H NMR (600 MHz, DMSO-*d*₆): δ 9.98 (s, 1H), 8.25 (t, *J* = 5.8 Hz, 1H), 7.94 (d, *J* = 1.7 Hz, 1H), 7.59 (dd, *J* = 12.8, 2.4 Hz, 1H), 7.55 (dd, *J* = 8.8, 8.8 Hz, 1H), 7.32 (d, *J* = 3.5 Hz), 7.30 (dd, *J* = 8.8, 2.2 Hz, 1H), 6.70 (dd, *J* = 3.5, 1.7 Hz, 1H), 4.76-4.72 (m, 1H), 4.14 (dd, *J* = 9.0, 8.9, 1H), 3.75 (dd, *J* = 9.0, 6.4 Hz, 1H), 3.42 (app t, *J* = 5.5 Hz, 2H), 1.84 (s, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆): δ 170.0, 156.4, 155.7 (d, *J* = 247 Hz), 154.0, 147.1, 145.9, 137.2 (d, *J* = 11 Hz), 127.5 (d, *J* = 2 Hz), 120.0 (d, *J* = 12 Hz), 114.9, 113.4 (d, *J* = 3 Hz), 112.2, 105.6 (d, *J* = 26 Hz), 71.7, 47.3, 41.4, 22.4; FTIR (ATR): ν 3310, 1764, 1677, 1657, 1350 cm⁻¹; HR-MS (ESI) *m/z*: found 384.0978; calculated for C₁₇H₁₆FN₃O₅Na [M+Na]⁺ 384.0972.



N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-methyl-2-furancarboxamide **43*


The title compound was prepared according to General Procedure B followed by trituration with CH₂Cl₂ to give **43** as a white powder (29 mg, 43%). *R*_f 0.14 (5% MeOH/CH₂Cl₂); ¹H NMR (600 MHz, DMSO-*d*₆): δ 9.71 (s, 1H), 8.25 (t, *J* = 5.9 Hz, 1H), 7.79 (d, *J* = 1.5 Hz, 1H), 7.59-7.56 (m, 2H), 7.28 (dd, *J* = 8.7, 2.0 Hz, 1H), 6.58 (d, *J* = 1.5 Hz, 1H), 4.76-4.72 (m, 1H), 4.13 (dd, *J* = 9.0, 9.0, 1H), 3.75 (dd, *J* = 9.0, 6.4 Hz, 1H), 3.43 (app t, *J* = 5.5 Hz, 2H), 2.32 (s, 3H), 1.84 (s, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆): δ 170.1, 157.4, 155.6 (d, *J* = 245 Hz), 154.1, 143.9, 141.6, 136.9 (d, *J* = 11 Hz), 127.9, 127.3, 120.3 (d, *J* = 13 Hz),

115.6, 113.4 (d, $J = 3$ Hz), 105.6 (d, $J = 26$ Hz), 71.7, 47.3, 41.4, 22.5, 11.0; FTIR (ATR): ν 3317, 1743, 1677, 1664, 1540 cm^{-1} ; HR-MS (ESI) m/z : found 398.1130; calculated for $\text{C}_{18}\text{H}_{18}\text{FN}_3\text{O}_5\text{Na}$ $[\text{M}+\text{Na}]^+$ 398.1128.



N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5-methyl-2-furancarboxamide **44*


The title compound was prepared according to General Procedure B to give **44** as an off-white powder (47 mg, 70%). R_f 0.13 (5% MeOH/ CH_2Cl_2); ^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ 9.82 (s, 1H), 8.25 (t, $J = 5.9$ Hz, 1H), 7.60-7.53 (m, 2H), 7.29 (dd, $J = 8.7, 1.9$ Hz, 1H), 7.21 (d, $J = 3.3$ Hz, 1H), 6.32 (d, $J = 3.3$ Hz, 1H), 4.77-4.72 (m, 1H), 4.13 (dd, $J = 9.0, 9.0$, 1H), 3.75 (dd, $J = 9.0, 6.5$ Hz, 1H), 3.42 (app t, $J = 5.5$ Hz, 2H), 2.37 (s, 3H), 1.84 (s, 3H); ^{13}C NMR (126 MHz, $\text{DMSO}-d_6$): δ 170.1, 156.6, 155.6 (d, $J = 245$ Hz), 155.3, 154.1, 145.6, 137.0 (d, $J = 10$ Hz), 127.4 (d, $J = 3$ Hz), 120.2 (d, $J = 13$ Hz), 116.2, 113.4 (d, $J = 3$ Hz), 108.6, 105.7 (d, $J = 26$ Hz), 71.7, 47.3, 41.4, 22.5, 13.6; FTIR (ATR): ν 3303, 1766, 1678, 1655, 1529 cm^{-1} ; HR-MS (ESI) m/z : found 398.1127; calculated for $\text{C}_{18}\text{H}_{18}\text{FN}_3\text{O}_5\text{Na}$ $[\text{M}+\text{Na}]^+$ 398.1128.



N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5-nitro-2-furancarboxamide **45*


The title compound was prepared according to General Procedure B but instead when the reaction was complete the mixture was filtered, and the solid was washed with CH_2Cl_2 (2 x 1 mL) and MeOH (1 mL) to give **45** as a white powder (32 mg, 44%). R_f 0.16 (5% MeOH/ CH_2Cl_2); ^1H NMR (600 MHz, $\text{DMSO}-d_6$): δ 10.55 (s, 1H), 8.25 (t, $J = 5.8$ Hz, 1H), 7.81 (d, $J = 3.9$ Hz, 1H), 7.64-7.61 (m, 2H), 7.56 (dd, $J = 8.8, 8.8$ Hz, 1H), 7.34 (dd, $J = 8.8, 2.0$ Hz,

1H), 4.77-4.73 (m, 1H), 4.15 (dd, $J = 9.0, 9.0$, 1H), 3.76 (dd, $J = 9.0, 6.5$ Hz, 1H), 3.43 (app t, $J = 5.5$ Hz, 2H), 1.84 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6): δ 170.0, 156.5 (d, $J = 246$ Hz), 155.0, 154.0, 151.8, 147.5, 137.8 (d, $J = 11$ Hz), 127.6, 119.1 (d, $J = 13$ Hz), 116.8, 113.5 (d, $J = 2$ Hz), 113.4, 105.7 (d, $J = 25$ Hz), 71.7, 47.2, 41.4, 22.5; FTIR (ATR): ν 3324, 1732, 1677, 1531 cm^{-1} ; HR-MS (ESI) m/z : found 429.0828; calculated for $\text{C}_{17}\text{H}_{15}\text{FN}_4\text{O}_7\text{Na}$ $[\text{M}+\text{Na}]^+$ 429.0822.




N*-[[[(5*S*)-3-[3-fluoro-4-(benzylamino)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **36*

To a stirred suspension of **10** (75 mg, 0.28 mmol) and benzaldehyde (0.035 mL, 0.34 mmol) in DCE (1.0 mL) was added STAB (0.27g, 1.3 mmol). The mixture was stirred at r.t. for 18 h, and then quenched with 1M NaOH (1 mL). After stirring for 5 min, water (5 mL) was added, then the mixture was extracted with CH_2Cl_2 (3 x 5 mL), dried (MgSO_4), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/ CH_2Cl_2) to yield the title compound **36** as a white powder (45 mg, 45%). R_f 0.11 (5% MeOH/ CH_2Cl_2); ^1H NMR (600 MHz, DMSO- d_6): δ 8.21 (bt, 1H), 7.39-7.28 (m, 5H), 7.21-7.19 (m, 1H), 6.90 (d, $J = 8.4$ Hz, 1H), 6.57 (dd, $J = 9.2, 8.4$ Hz, 1H), 6.12 (bt, 1H), 4.66-4.61 (m, 1H), 4.33 (d, $J = 6.0$ Hz, 2H), 3.99 (dd, $J = 9.4, 9.4$ Hz, 1H), 3.61 (dd, $J = 6.5, 8.6$ Hz, 1H), 3.36 (m, under H_2O signal, 2H assumed), 1.82 (s, 3H); ^{13}C NMR (151 MHz, DMSO- d_6): δ 170.0, 154.2, 150.2 (d, $J = 238$), 139.9, 133.0 (d, $J = 12$ Hz), 128.3, 127.3 (d, $J = 9$ Hz), 127.0, 126.6, 115.0, 112.2 (d, $J = 5$ Hz), 106.5 (d, $J = 23$ Hz), 71.3, 47.6, 46.0, 41.5, 22.4; FTIR (ATR): ν 3295, 1730, 1644, 1526 cm^{-1} ; HR-MS (ESI) m/z : found 358.1569; calculated for $\text{C}_{19}\text{H}_{21}\text{FN}_3\text{O}_3$ $[\text{M}+\text{H}]^+$ 358.1567.



N*-[[[(5*S*)-3-[3-fluoro-4-[(phenylsulfonyl)amino]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **37*


To a stirred suspension of **10** (48 mg, 0.18 mmol) in CH₂Cl₂ (1.0 mL) was added pyridine (0.029 mL, 0.22 mmol) and phenylsulfonyl chloride (0.028 mL, 0.22 mmol). The mixture was stirred at r.t. for 18 h, and then quenched with saturated aqueous NaHCO₃ (5 mL) and extracted with CH₂Cl₂ (3 x 5 mL), dried (MgSO₄), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/CH₂Cl₂) to yield the title compound **37** as a white powder (36 mg, 49%). *R*_f 0.06 (5% MeOH/ CH₂Cl₂); ¹H NMR (600 MHz, DMSO-*d*₆): δ 10.06 (bs, 1H), 8.21 (t, *J* = 5.8 Hz, 1H), 7.70-7.68 (m, 2H), 7.65-7.62 (m, 1H), 7.56-7.53 (m, 2H), 7.45-7.42 (m, 1H), 7.22-7.19 (m, 2H), 4.71-4.67 (m, 1H), 4.05 (dd, *J* = 9.0, 9.0 Hz, 1H), 3.67 (dd, *J* = 9.0, 6.5 Hz, 1H), 3.39-3.37 (m, 2H), 1.81 (s, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆): δ 170.0, 156.1 (d, *J* = 246 Hz), 153.9, 140.0, 137.6 (d, *J* = 10 Hz), 132.9, 129.2, 127.9, 126.6, 119.1 (d, *J* = 13 Hz), 113.6 (d, *J* = 3 Hz), 105.5 (d, *J* = 26 Hz), 71.7, 47.1, 41.3, 22.4; FTIR (ATR): ν 3403, 1750, 1659, 1513 cm⁻¹; HR-MS (ESI) *m/z*: found 408.1027; calculated for C₁₈H₁₉FN₃O₅S [M+H]⁺ 408.1029.



N*-[[[(5*S*)-3-[3-fluoro-4-(ethylamino)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **21*


To a stirred suspension of **10** (50 mg, 0.19 mmol) and K₂CO₃ (49 mg, 0.36 mmol) in DMF (1 mL) was added ethyl bromide (0.2 mL, 3 mmol). The mixture was heated at 60 °C in a sealed tube for 18 h, then diluted with EtOAc (5 mL), washed with water (3 x 5 mL), dried (MgSO₄), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/CH₂Cl₂), followed by C18 silica chromatography (5-50% MeCN/H₂O) to yield the title compound **21** as an off-white powder (20 mg, 36%). *R*_f 0.25 (5% MeOH/ CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃): δ 7.31 (dd, *J* = 13.3, 2.5 Hz, 1H),

6.95 (ddd, $J = 8.7, 2.5, 1.1$ Hz, 1H), 6.62 (dd, $J = 9.1, 8.7$ Hz, 1H), 6.61 (bs, 1H), 4.76-4.71 (m, 1H), 3.96 (dd, $J = 9.1, 9.0$ Hz, 1H), 3.73 (bs, 1H), 3.71 (dd, $J = 9.1, 6.7$ Hz, 1H), 3.65 (ddd, $J = 14.7, 6.0, 3.3$ Hz, 1H), 3.58 (ddd, $J = 14.7, 6.0, 6.0$ Hz, 1H), 3.15 (q, $J = 7.1$ Hz, 1H), 2.00 (s, 3H), 1.26 (t, $J = 7.1$ Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ 171.4, 154.9, 151.0 (d, $J = 239$ Hz), 134.2 (d, $J = 12$ Hz), 127.4 (d, $J = 10$ Hz), 115.3 (d, $J = 3$ Hz), 111.9 (d, $J = 5$ Hz), 107.2 (d, $J = 24$ Hz), 72.0, 48.2, 42.1, 38.4, 23.1, 14.8; FTIR (ATR): ν 3330, 1734, 1667, 1525 cm^{-1} ; HR-MS (ESI) m/z : found 296.1415; calculated for $\text{C}_{14}\text{H}_{19}\text{N}_3\text{O}_3\text{F}$ $[\text{M}+\text{H}]^+$ 296.1410.




N*-[[[(5*S*)-3-[3-fluoro-4-(allylamino)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **22*

To a stirred suspension of **10** (100 mg, 0.37 mmol) and K_2CO_3 (103 mg, 0.75 mmol) in DMF (1.0 mL) was added allyl bromide (45 mg, 0.37 mmol) in DMF (1.0 mL). The mixture was stirred at r.t. for 18 h, then quenched with water (5 mL) and extracted with CH_2Cl_2 (2 x 5 mL), washed with water (2 x 5 mL), dried (MgSO_4), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% $\text{MeOH}/\text{CH}_2\text{Cl}_2$) to yield the title compound **22** as a yellow resin (24 mg, 28%). R_f 0.19 (5% $\text{MeOH}/\text{CH}_2\text{Cl}_2$); ^1H NMR (600 MHz, CDCl_3): δ 7.35 (dd, $J = 13.2, 2.5$ Hz, 1H), 6.95 (ddd, $J = 8.8, 2.5, 1.2$ Hz, 1H), 6.65 (dd, $J = 9.1, 8.8$ Hz, 1H), 6.22 (t, $J = 5.9$ Hz, 1H), 5.96-5.90 (m, 1H), 5.29-5.26 (m, 1H), 5.19-5.17 (m, 1H), 4.76-4.72 (m, 1H), 4.01 (bs, 1H), 3.98 (dd, $J = 9.1, 8.9$ Hz, 1H), 3.80 (d, $J = 5.3$ Hz, 2H), 3.71 (dd, $J = 9.1, 6.7$ Hz, 1H), 3.69 (ddd, 14.7, 6.1, 3.2 Hz, 1H), 3.58 (ddd, 14.7, 6.1, 6.1 Hz, 1H), 2.02 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): δ 171.2, 154.87, 151.2 (d, $J = 239$ Hz), 134.9, 133.8 (d, $J = 12$ Hz), 127.8 (d, $J = 10$ Hz), 116.7, 115.1 (d, $J = 3$ Hz), 112.3 (d, $J = 4$ Hz), 107.2 (d, $J = 24$ Hz), 71.9, 48.2, 46.3, 42.2, 23.3; FTIR (ATR): ν 3288, 1730, 1645, 1526 cm^{-1} ; HR-MS (ESI) m/z : found 308.14156; calculated for $\text{C}_{15}\text{H}_{19}\text{FN}_3\text{O}_3$ $[\text{M}+\text{H}]^+$ 308.1410.




(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-N-methylacetamide **24**

The title compound was prepared according to General Procedure A to give **24** as a colourless resin (46 mg, 80%). R_f 0.20 (5% MeOH/ CHCl_3); ^1H NMR (500 MHz, CDCl_3): δ 7.57 (d, $J = 11.7$ Hz, 1H), 7.24-7.19 (m, 2H), 6.86 (t, $J = 6.1$ Hz, 1H), 4.82-4.77 (m, 1H), 4.06 (dd, $J = 9.1, 8.9$ Hz, 1H), 3.82 (dd, $J = 9.1, 6.7$ Hz, 1H), 3.65-3.63 (m, 2H), 3.16 (s, 3H), 2.00 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3): δ 171.6, 171.1, 158.0 (d, $J = 249$ Hz), 154.3, 139.1 (d, $J = 10$ Hz), 129.7 (d, $J = 2$ Hz), 127.6 (d, $J = 14$ Hz), 114.1 (d, $J = 3$ Hz), 107.1 (d, $J = 26$ Hz), 72.3, 47.6, 41.9, 36.5, 23.0, 21.8. FTIR (ATR): ν 3298, 1748, 1646, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 324.1363; calculated for $\text{C}_{15}\text{H}_{19}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 324.1360.




(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-N-methylpropanamide **25**

The title compound was prepared according to General Procedure A to give **25** as a colourless resin (50 mg, 83%). R_f 0.26 (5% MeOH/ CHCl_3); ^1H NMR (500 MHz, CDCl_3): δ 7.57 (d, $J = 11.6$ Hz, 1H), 7.23-7.19 (m, 2H), 6.80 (t, $J = 5.8$ Hz, 1H), 4.82-4.77 (m, 1H), 4.06 (dd, $J = 9.1, 8.9$ Hz, 1H), 3.82 (dd, $J = 9.1, 6.7$ Hz, 1H), 3.66-3.63 (m, 2H), 3.16 (s, 3H), 2.05-2.00 (m, 5H) 1.00 (t, $J = 7.5$ Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 174.4, 171.6, 158.1 (d, $J = 249$ Hz), 154.3, 139.1 (d, $J = 10$ Hz), 130.0 (d, $J = 2$ Hz), 127.2 (d, $J = 14$ Hz), 114.1 (d, $J = 3$ Hz), 107.1 (d, $J = 26$ Hz), 72.2, 47.6, 41.9, 36.6, 27.0, 23.1, 9.5; FTIR (ATR): ν 3298, 1748, 1646, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 338.1514; calculated for $\text{C}_{16}\text{H}_{21}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 338.1516.



(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-N-methylbutanamide 26


The title compound was prepared according to General Procedure A to give **26** as a colourless resin (52 mg, 82%). R_f 0.29 (5% MeOH/ CHCl_3); ^1H NMR (600 MHz, CDCl_3): δ 7.59 (d, J = 11.8 Hz, 1H), 7.24-7.20 (m, 2H), 6.16 (bs), 4.82-4.79 (m, 1H), 4.07 (dd, J = 9.1, 8.9 Hz, 1H), 3.82 (dd, J = 9.1, 6.8 Hz, 1H), 3.72 (ddd, J = 14.7, 6.1, 3.5 Hz, 1H), 3.64 (ddd, J = 14.7, 6.1, 6.1 Hz, 1H), 3.20 (s, 3H), 2.03 (s, 3H), 2.00 (t, J = 7.5 Hz, 2H), 1.61-1.55 (m, 2H), 0.82 (t, J = 7.4 Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3): δ 173.5, 171.3, 158.3 (d, J = 250 Hz), 154.2, 139.0 (d, J = 10 Hz), 130.2 (d, J = 2 Hz), 127.5 (d, J = 13 Hz), 114.1 (d, J = 3 Hz), 107.2 (d, J = 26 Hz), 72.2, 47.6, 42.0, 36.6, 35.7, 23.3, 18.7, 13.9; FTIR (ATR): ν 3300, 1748, 1646, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 352.1674; calculated for $\text{C}_{17}\text{H}_{23}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 352.1673.



(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-N-methylpentanamide 27


The title compound was prepared according to General Procedure A to give **27** as a colourless resin (52 mg, 80%). R_f 0.32 (5% MeOH/ CHCl_3); ^1H NMR (600 MHz, CDCl_3): δ 7.59 (d, J = 11.6 Hz, 1H), 7.24-7.20 (m, 2H), 6.06 (bs), 4.82-4.79 (m, 1H), 4.07 (dd, J = 9.0, 8.9 Hz, 1H), 3.82 (dd, J = 9.0, 6.8 Hz, 1H), 3.73 (ddd, J = 14.7, 5.9, 3.5 Hz, 1H), 3.64 (ddd, J = 14.7, 6.1, 6.1 Hz, 1H), 3.20 (s, 3H), 2.04-2.02 (m, 5H), 1.57-1.51 (m, 2H), 1.21 (tt, J = 7.5 Hz, 7.4 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3): δ 173.7, 171.2, 158.3 (d, J = 250 Hz), 154.1, 139.0 (d, J = 10 Hz), 130.1 127.6 (d, J = 13 Hz), 114.0 (d, J = 3 Hz), 107.2 (d, J = 26 Hz), 72.1, 47.6, 42.1, 36.6, 33.5, 27.5, 23.3, 22.5, 13.9; FTIR (ATR): ν 3299,

1748, 1646, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 366.1825; calculated for $\text{C}_{18}\text{H}_{25}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 366.1829.



(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-N-methylhexanamide 28


The title compound was prepared according to General Procedure A to give **28** as a colourless resin (59 mg, 87%). R_f 0.32 (5% MeOH/ CHCl_3); ^1H NMR (600 MHz, CDCl_3): δ 7.59 (d, $J = 11.3$ Hz, 1H), 7.24-7.20 (m, 2H), 6.06 (bs), 4.83-4.79 (m, 1H), 4.07 (dd, $J = 9.0$, 8.9 Hz, 1H), 3.82 (dd, $J = 9.0$, 6.8 Hz, 1H), 3.73 (ddd, $J = 14.7$, 5.8, 3.4 Hz, 1H), 3.64 (ddd, $J = 14.7$, 6.1, 6.1 Hz, 1H), 3.20 (s, 3H), 2.04-2.01 (m, 5H), 1.58-1.53 (m, 2H), 1.25-1.13 (m, 4H), 0.83 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3): δ 173.7, 171.2, 158.3 (d, $J = 250$ Hz), 154.1, 139.0 (d, $J = 10$ Hz), 130.1 127.6 (d, $J = 13$ Hz), 114.0 (d, $J = 3$ Hz), 107.2 (d, $J = 26$ Hz), 72.1, 47.6, 42.1, 36.6, 33.7, 31.5, 25.0, 23.3, 22.5, 14.0; FTIR (ATR): ν 3302, 1749, 1646, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 380.1986; calculated for $\text{C}_{19}\text{H}_{27}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 380.1986.



(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-N-methylnonanamide 29


The title compound was prepared according to General Procedure B to give **29** as a colourless resin (45 mg, 60%). R_f 0.13 (5% MeOH/ CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3): δ 7.60-7.57 (m, 1H), 7.22-7.19 (m, 2H), 6.12 (t, $J = 5.6$ Hz, 1H), 4.82-4.79 (m, 1H), 4.07 (dd, $J = 9.0$, 9.0 Hz, 1H), 3.82 (dd, $J = 9.0$, 6.8 Hz, 1H), 3.72 (ddd, $J = 14.7$, 6.1, 3.4 Hz, 1H), 3.63 (ddd, $J = 14.7$, 6.1, 6.1 Hz, 1H), 3.19 (s, 3H), 2.03 (s, 3H), 2.02 (t, $J = 7.6$ Hz, 2H), 1.57-1.51 (m, 2H), 1.27-1.15 (m, 10H), 0.85 (t, $J = 7.0$, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 173.7, 171.3,

154.0, 158.3 (d, $J = 250$ Hz), 154.2, 139.0 (d, $J = 10$ Hz), 130.1, 127.6 (d, $J = 14$ Hz), 114.0 (d, $J = 3$ Hz), 107.2 (d, $J = 26$ Hz), 72.2, 47.6, 42.1, 36.6, 33.8, 31.9, 29.4, 29.4, 29.2, 25.4, 23.3, 22.8, 14.2; FTIR (ATR): ν 3302, 1751, 1648, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 444.2265; calculated for $\text{C}_{22}\text{H}_{32}\text{FN}_3\text{O}_4\text{Na}$ $[\text{M}+\text{Na}]^+$ 444.2275.



(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-N-methylisobutyramide 30


The title compound was prepared according to General Procedure A to give **30** as a colourless resin (50 mg, 80%). R_f 0.30 (5% MeOH/ CHCl_3); ^1H NMR (600 MHz, CDCl_3): δ 7.60-7.58 (m, 1H), 7.24-7.21 (m, 2H), 6.10 (t, $J = 5.8$ Hz, 1H), 4.83-4.78 (m, 1H), 4.07 (dd, $J = 9.0, 8.9$ Hz, 1H), 3.82 (dd, $J = 9.0, 6.8$ Hz, 1H), 3.72 (ddd, $J = 14.7, 5.8, 3.8$ Hz, 1H), 3.66-3.62 (m, 1H), 3.19 (s, 3H), 2.40 (sept, $J = 6.7$ Hz, 1H), 2.03 (s, 3H), 1.02 (d, $J = 6.7$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3): δ 177.9, 171.2, 158.3 (d, $J = 249$ Hz), 154.2, 139.0 (d, $J = 10$ Hz), 130.1, 127.5 (d, $J = 14$ Hz), 114.1, 107.2 (d, $J = 26$ Hz), 72.2, 47.6, 42.0, 36.8, 31.3, 23.3, 19.9, 19.5; FTIR (ATR): ν 3298, 1749, 1646, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 352.1674; calculated for $\text{C}_{17}\text{H}_{23}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 352.1673.



(S)-N-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-N,3-dimethylbutanamide 31


The title compound was prepared according to General Procedure A to give **31** as a colourless resin (39 mg, 60%). R_f 0.15 (5% MeOH/ CH_2Cl_2); ^1H NMR (600 MHz, CDCl_3): δ 7.59 (d, $J = 11.7$ Hz, 1H), 7.24-7.18 (m, 2H), 6.04 (t, $J = 6.0$ Hz, 1H), 4.82-4.79 (m, 1H), 4.08 (dd, $J = 8.9, 8.9$ Hz, 1H), 3.82 (dd, $J = 8.9, 6.8$ Hz, 1H), 3.73 (ddd, $J = 14.7, 6.0, 3.3$ Hz, 1H), 3.63 (ddd, $J = 14.7, 6.0, 6.0$ Hz, 1H), 3.20 (s, 3H), 2.12 (dsept, 7.0, 6.7 Hz, 1H), 2.03 (s,

3H), 1.92 (d, $J = 7.0$ Hz, 2H), 0.83 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (151 MHz, CDCl_3): δ 173.0, 171.2, 158.2 (d, $J = 250$ Hz), 154.1, 139.0 (d, $J = 11$ Hz), 130.2, 127.6 (d, $J = 14$ Hz), 114.0 (d, $J = 3$ Hz), 107.1 (d, $J = 26$ Hz), 72.1, 47.6, 42.5, 42.1, 36.6, 25.8, 23.3, 22.7, 22.6; FTIR (ATR): ν 3309, 1749, 1646, 1517 cm^{-1} ; HR-MS (ESI) m/z : found 388.1650; calculated for $\text{C}_{18}\text{H}_{24}\text{FN}_3\text{O}_4\text{Na}$ $[\text{M}+\text{Na}]^+$ 388.1649.



(*S*)-*N*-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)-*N*-methylbenzamide **46**


The title compound was prepared according to General Procedure B to give **46** as a colourless resin (35 mg, 51%). R_f 0.15 (5% MeOH/ CH_2Cl_2); ^1H NMR (600 MHz, CDCl_3): δ 7.44 (d, $J = 11.6$ Hz, 1H), 7.31 (bs, 1H), 7.25 (bs, 1H), 7.18 (bs, 2H), 7.02 (bs, 2H), 6.11 (bt, 1H), 4.75-4.73 (m, 1H), 3.96 (dd, $J = 9.0, 9.0$ Hz, 1H), 3.70 (dd, 9.0, 7.2 Hz, 1H), 3.66 (ddd, $J = 14.7, 6.1, 3.4$ Hz, 1H), 3.58 (ddd, $J = 14.7, 6.1, 6.0$ Hz, 1H), 3.39 (s, 3H), 1.99 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): δ 171.4, 171.2, 157.5 (d, $J = 250$ Hz), 154.1, 138.4 (d, $J = 9$ Hz), 135.7, 130.0, 130.0, 128.5 (d, $J = 10$ Hz), 128.1, 113.5, 106.7 (d, $J = 26$ Hz), 72.1, 47.5, 42.0, 37.6, 23.2; FTIR (ATR): ν 3301, 1748, 1639, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 408.1356; calculated for $\text{C}_{20}\text{H}_{20}\text{FN}_3\text{O}_4\text{Na}$ $[\text{M}+\text{Na}]^+$ 408.1336.



N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-*N*-methyl-2-pyridinecarboxamide **49*


The title compound was prepared according to General Procedure B but instead using pyridine-2-carbonyl chloride hydrochloride (64 mg, 0.36 mmol) and pyridine (0.04 mL, 0.5 mmol) to give **49** as a light yellow resin (36 mg, 52%). R_f 0.40 (10% MeOH/ CH_2Cl_2); ^1H NMR (600 MHz, CDCl_3): δ 8.25 (m, 1H), 7.64-7.62 (m, 1H), 7.59-7.58 (m, 1H), 7.42-

7.40 (m, 1H), 7.14-7.12 (m, 1H), 7.11-7.08 (m, 1H), 6.99-9.98 (m, 1H), 6.25 (bt, 1H), 4.75-4.71 (m, 1H), 3.97 (dd, $J = 8.9, 8.9$ Hz), 3.73-3.70 (m, 1H), 3.66 (ddd, $J = 14.6, 6.1, 3.5$ Hz, 1H), 3.59-3.55 (m, 1H), 3.42 (s, 3H), 1.99 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): δ 171.3, 169.0, 157.5 (d, $J = 249$ Hz), 154.1, 153.6, 148.3, 138.2 (d, $J = 10$ Hz), 136.6, 129.7, 128.3 (d, $J = 12$ Hz), 124.5, 123.6, 113.3, 106.4 (d, $J = 26$ Hz), 72.1, 47.5, 42.1, 37.6, 23.2; FTIR (ATR): ν 3300, 1747, 1645, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 409.1288; calculated for $\text{C}_{19}\text{H}_{19}\text{FN}_4\text{O}_4\text{Na}$ $[\text{M}+\text{Na}]^+$ 409.1288.




N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-*N*-methyl-4-pyridinecarboxamide **50*

The title compound was prepared according to General Procedure B but instead using pyridine-4-carbonyl chloride hydrochloride (64 mg, 0.36 mmol) and pyridine (0.04 mL, 0.5 mmol) to give **50** as a white powder (28 mg, 41%). R_f 0.42 (10% MeOH/ CH_2Cl_2); ^1H NMR (600 MHz, CDCl_3): δ 8.47-8.46 (m, 2H), 7.44 (d, $J = 11.6$ Hz, 1H), 7.15-7.14 (m, 2H), 7.07-7.04 (m, 2H), 6.29 (bs, 1H), 4.77-4.73 (m, 1H), 3.96 (dd, $J = 8.9, 8.9$ Hz, 1H), 3.71 (dd, $J = 8.9, 6.8$ Hz, 1H), 3.65 (ddd, 14.6, 6.0, 3.4 Hz, 1H), 3.59 (ddd, 14.6, 5.8, 5.8 Hz, 1H), 3.39 (s, 3H), 1.98 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): δ 171.3, 169.0, 157.5 (d, $J = 249$ Hz), 154.0, 149.9, 143.4, 139.2 (d, $J = 10$ Hz), 129.8, 127.0 (d, $J = 13$ Hz), 121.9, 113.7, 106.7 (d, $J = 26$ Hz), 72.2, 47.4, 42.0, 37.4, 23.2; FTIR (ATR): ν 3301, 1748, 1650, 1518 cm^{-1} ; HR-MS (ESI) m/z : found 387.1469; calculated for $\text{C}_{19}\text{H}_{20}\text{FN}_4\text{O}_4$ $[\text{M}+\text{H}]^+$ 387.1469.




N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-*N*-methyl-2-thiophenecarboxamide **51*

The title compound was prepared according to General Procedure B to give **51** as a colourless resin (56 mg, 80%). R_f 0.09 (5% MeOH/CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃): δ 7.59 (bd, 1H), 7.31 (dd, J = 5.0, 1.0 Hz, 1H), 7.26 (dd, J = 8.5, 8.5 Hz, 1H), 7.22-7.18 (bm, 1H), 6.99 (bd, 1H), 6.83 (dd, J = 5.0, 4.0 Hz, 1H), 6.20 (t, J = 6.0, 1H), 4.83-4.78 (m, 1H), 4.07 (dd, J = 9.0, 9.0, 1H), 3.81 (dd, J = 9.0, 6.7 Hz, 1H), 3.72 (ddd, J = 14.7, 6.0, 3.5 Hz, 1H), 3.63 (ddd, J = 14.7, 6.0, 6.0 Hz, 1H), 3.38 (s, 3H), 2.03 (s, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 171.3, 163.3, 158.5 (d, J = 250 Hz), 154.1, 139.5 (d, 10 Hz), 137.1, 132.1, 130.7, 127.6 (d, J = 13 Hz), 126.9, 113.9 (d, J = 3 Hz), 107.1 (d, J = 26 Hz), 72.2, 47.6, 42.1, 38.3, 23.3; FTIR (ATR): ν 3299, 1748, 1627, 1516 cm⁻¹; HR-MS (ESI) m/z : found 414.0904; calculated for C₁₈H₁₈FN₃O₄SNa [M+Na]⁺ 414.0900.




N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-*N*-methyl-3-thiophenecarboxamide **52*

The title compound was prepared according to General Procedure B to give **52** as a colourless resin (60 mg, 86%). R_f 0.08 (5% MeOH/CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃): δ 7.52-7.50 (m, 1H), 7.26 (bs, 1H), 7.14-7.07 (m, 3H), 6.97 (bs, 1H), 6.29 (t, J = 6.0 Hz, 1H), 4.80-4.75 (m, 1H), 4.02 (dd, J = 9.0, 9.0, 1H), 3.77 (dd, J = 9.0, 6.8 Hz, 1H), 3.68 (ddd, J = 14.7, 6.0, 3.5 Hz, 1H), 3.61 (ddd, J = 14.7, 6.0, 6.0 Hz, 1H), 3.36 (s, 3H), 2.01 (s, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 171.3, 165.8, 157.8 (d, J = 250 Hz), 154.1, 138.7 (d, 10 Hz), 136.4, 129.9, 129.1, 128.2 (d, J = 13 Hz), 128.0, 125.0, 113.7 (d, J = 3 Hz), 106.9 (d, J = 26 Hz), 72.1, 47.5, 42.0, 37.7, 23.2; FTIR (ATR): ν 3300, 1748, 1634, 1517 cm⁻¹; HR-MS (ESI) m/z : found 414.0896; calculated for C₁₈H₁₈FN₃O₄SNa [M+Na]⁺ 414.0900.




N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-*N*-methyl-3-methyl-2-furan carboxamide **53*

The title compound was prepared according to General Procedure B to give **53** as a colourless resin (44 mg, 64%). R_f 0.18 (5% MeOH/CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃): δ 7.52 (d, J = 11.9 Hz, 1H), 7.13-7.09 (m, 2H), 6.96 (bs, 1H), 6.27 (t, J = 5.8 Hz, 1H), 6.18 (bs, 1H), 4.80-4.76 (m, 1H), 4.05 (dd, J = 9.0, 8.9 Hz, 1H), 3.78 (dd, J = 9.0, 6.7 Hz, 1H), 3.70 (ddd, 14.7, 6.1, 3.4 Hz, 1H), 3.62 (ddd, 14.7, 6.1, 6.1 Hz, 1H), 3.35 (s, 3H), 2.28 (s, 3H), 2.02 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): δ 171.3, 161.2, 158.0 (d, J = 249 Hz), 154.2, 142.7, 142.6, 138.1 (d, J = 10 Hz), 129.4 (d, J = 2 Hz), 129.2, 128.2 (d, J = 13 Hz), 114.6, 113.4, 106.6 (d, J = 26 Hz), 72.1, 47.6, 42.1, 37.6, 23.2, 11.6; FTIR (ATR): ν 3301, 1748, 1635, 1518 cm⁻¹; HR-MS (ESI) m/z : found 412.1287; calculated for C₁₉H₂₀FN₃O₅Na [M+Na]⁺ 412.1285.




N*-[4-[(5*S*)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-*N*,5-methyl-2-furan carboxamide **54*

The title compound was prepared according to General Procedure B to give **54** as a colourless resin (60 mg, 87%). R_f 0.18 (5% MeOH/CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃): δ 7.57 (bd, 1H), 7.24-7.18 (m, 2H), 6.44 (bs, 1H), 5.94 (bs, 1H), 5.84 (bs, 1H), 4.83-4.78 (m, 1H), 4.07 (dd, J = 9.0, 9.0 Hz, 1H), 3.83 (dd, J = 9.0, 6.7 Hz, 1H), 3.70 (ddd, 14.7, 6.1, 3.7 Hz, 1H), 3.64 (ddd, 14.7, 6.1, 6.0 Hz, 1H), 3.34 (s, 3H), 2.18 (s, 3H), 2.02 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): δ 171.4, 159.8, 158.3 (d, J = 250 Hz), 155.3, 154.2, 145.2, 139.0 (d, J = 10 Hz), 130.2, 127.7 (d, J = 13 Hz), 117.7, 113.7 (d, J = 3 Hz), 107.8, 106.9 (d, J = 26 Hz), 72.1, 47.7, 42.1, 37.7, 23.2, 13.8; FTIR (ATR): ν 3300, 1749, 1634, 1514 cm⁻¹; HR-MS (ESI) m/z : found 412.1286; calculated for C₁₉H₂₀FN₃O₅Na [M+Na]⁺ 412.1285.



N*-[[[(5*S*)-3-[3-fluoro-4-(benzylmethylamino)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **47*


To a stirred suspension of **23** (50 mg, 0.18 mmol) and K₂CO₃ (49 mg, 0.36 mmol) in DMF (1.0 mL) was added benzyl bromide (0.025 mL, 0.21 mmol). The mixture was then stirred at r.t. for 18 h, and then quenched with water (10 mL) and extracted with CH₂Cl₂ (4 x 5 mL), washed with water (3 x 5 mL), dried (MgSO₄), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/CH₂Cl₂) and co-evaporated with 1:1 MeOH/H₂O (2 mL) to yield the title compound **47** as a white powder (39 mg, 60%). R_f 0.19 (5% MeOH/CH₂Cl₂); ¹H NMR (600 MHz, DMSO-*d*₆): δ 8.23 (t, *J* = 5.8 Hz, 1H), 7.48 (dd, *J* = 15.2, 2.6 Hz, 1H), 7.32-7.30 (m, 2H), 7.26-7.23 (m, 3H), 7.11 (ddd, *J* = 8.8, 2.6, 0.6 Hz, 1H), 6.97 (dd, *J* = 9.9, 8.8 Hz, 1H), 4.69 (m, 1H), 4.23 (s, 2H), 4.06 (dd, *J* = 9.1, 8.9, 1H), 3.69 (dd, *J* = 9.1, 6.4 Hz, 1H), 3.39 (dd, *J* = 5.6, 5.6 Hz, 2H), 2.67 (s, 3H), 1.83 (s, 2H); ¹³C NMR (151 MHz, DMSO-*d*₆): δ 170.0, 154.1 (d, *J* = 243 Hz), 154.1, 138.0, 135.4 (d, *J* = 8 Hz), 132.3 (d, *J* = 11 Hz), 128.3, 128.1, 127.1, 119.8 (d, *J* = 4 Hz), 114.0 (d, *J* = 2 Hz), 106.8 (d, *J* = 26 Hz), 71.5, 58.4 (d, *J* = 5 Hz), 47.3, 41.4, 39.4, 22.5; FTIR (ATR): ν 3293, 1739, 1660, 1516 cm⁻¹; HR-MS (ESI) *m/z*: found 372.1722; calculated for C₂₀H₂₃FN₃O₃ [M+H]⁺ 372.1723.



N*-[[[(5*S*)-3-[3-fluoro-4-[methyl(phenylsulfonyl)amino]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **48*


To a stirred suspension of **23** (50 mg, 0.18 mmol) in CH₂Cl₂ (1.0 mL) was added pyridine (0.029 mL, 0.22 mmol) and phenylsulfonyl chloride (0.028 mL, 0.22 mmol). The mixture was then stirred at r.t. for 18 h, and then quenched with saturated aqueous NaHCO₃ (5 mL) and extracted with CH₂Cl₂ (3 x 5 mL), dried (MgSO₄), filtered and concentrated under

reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/CH₂Cl₂) to yield the title compound **48** as a colourless resin (62 mg, 83%). *R*_f 0.09 (5% MeOH/CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃): δ 7.68-7.67 (m, 2H), 7.62-7.59 (m, 1H), 7.50-7.47 (m, 3H), 7.29 (dd, *J* = 8.6, 8.6, 1H), 7.11 (dd, *J* = 8.6, 2.0 Hz, 1H), 6.21 (t, *J* = 6.0 Hz, 1H), 4.81-4.76 (m, 1H), 4.04 (dd, *J* = 9.0, 9.0 Hz, 1H), 3.78 (dd, *J* = 9.0, 6.8 Hz, 1H), 3.69 (ddd, *J* = 14.7, 6.1, 3.5 Hz, 1H), 3.62 (ddd, *J* = 14.7, 6.1, 6.1 Hz, 1H), 3.19 (d, *J* = 0.9 Hz, 3H), 2.02 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): δ 171.3, 159.5 (d, *J* = 253 Hz), 154.1, 139.2 (d, *J* = 10 Hz), 138.0, 133.1, 131.9 (d, *J* = 2 Hz), 129.1, 127.6, 124.1 (d, *J* = 12 Hz), 113.4 (d, *J* = 3 Hz), 106.9 (d, *J* = 26 Hz), 72.1, 47.6, 42.0, 38.2 (d, *J* = 4 Hz), 23.2; FTIR (ATR): ν 3299, 1748, 1656, 1514 cm⁻¹; HR-MS (ESI) *m/z*: found 444.1022; calculated for C₁₉H₂₀FN₃O₅SNa [M+Na]⁺ 444.1005.




N*-[[*(5S)*-3-[3-fluoro-4-(ethylmethylamino)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **32*

To a stirred suspension of **23** (50 mg, 0.18 mmol) and K₂CO₃ (49 mg, 0.36 mmol) in dried DMF (1 mL) under N₂ was added ethyl bromide (0.5 mL, 7 mmol). The mixture was then heated at 60 °C for 18 h, then diluted with EtOAc (5 mL), washed with water (3 x 5 mL), and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/CH₂Cl₂), followed by C18 silica chromatography (5-50% MeCN/H₂O) to yield the title compound **32** as an off-white powder (25 mg, 45%). *R*_f 0.21 (5% MeOH/CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃): δ 7.33 (dd, *J* = 14.6, 2.6 Hz, 1H), 7.01 (ddd, *J* = 8.8, 2.6, 0.9 Hz, 1H), 6.85 (dd, *J* = 9.2, 8.8, 1H), 6.71 (t, *J* = 6.0, 1H), 4.77-4.72 (m, 1H), 3.99 (dd, *J* = 9.1, 9.0 Hz, 1H), 3.73 (dd, *J* = 9.1, 6.7 Hz, 1H), 3.67-3.57 (m, 2H), 3.14 (q, *J* = 7.1 Hz, 2H), 2.76 (s, 3H), 2.00 (s, 3H), 1.07 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 171.5, 155.0 (d, *J* = 245 Hz), 154.7, 136.7 (d, *J* = 9 Hz), 131.4 (d, *J* = 10 Hz), 119.4 (d, *J* = 5 Hz), 114.2 (d, *J* = 3 Hz), 107.8 (d, *J* = 27 Hz), 72.1, 49.5 (d, *J* = 5 Hz), 47.8, 42.0, 39.3 (*J* = 2 Hz), 23.1, 12.0; FTIR (ATR): ν 3335, 1733, 1658, 1517 cm⁻¹; HR-MS (ESI) *m/z*: found 310.1574; calculated for C₁₅H₂₁N₃O₃F [M+H]⁺ 310.1567.



N*-[[*(5S)*]-3-[3-fluoro-4-[allylmethylamino]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **33*


To a stirred suspension of **23** (50 mg, 0.18 mmol) and K₂CO₃ (49 mg, 0.36 mmol) in DMF (1.0 mL) was added allyl bromide (0.02 mL, 0.2 mmol). The mixture was stirred at r.t. for 18 h, then diluted with CH₂Cl₂ (2 mL), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/CH₂Cl₂) to yield the title compound **33** as a peach resin (21 mg, 37%). R_f 0.21 (5% MeOH/CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃): δ 7.37 (dd, *J* = 14.5, 2.6 Hz, 1H), 7.03 (ddd, *J* = 8.8, 2.6, 0.9 Hz, 1H), 6.87 (dd, *J* = 9.2, 8.8 Hz, 1H), 6.20 (t, *J* = 6.1 Hz, 1H), 5.88-5.81 (m, 1H), 5.22-5.18 (m, 1H), 5.17-5.14 (m, 1H), 4.77-4.73 (m, 1H), 4.01 (dd, *J* = 9.0, 8.9 Hz, 1H), 3.73 (dd, *J* = 9.0, 6.7 Hz, 1H), 3.70 (d, *J* = 6.1 Hz, 2H), 3.70 (ddd, 14.7, 6.1, 3.2 Hz, 1H), 3.60 (ddd, 14.7, 6.1, 6.1 Hz, 1H), 2.78 (s, 3H), 2.02 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): δ 171.2, 154.9 (d, *J* = 245 Hz), 154.5, 136.7 (d, *J* = 9 Hz), 134.4, 131.5 (d, *J* = 10 Hz), 119.4 (d, *J* = 4 Hz), 117.7, 114.1 (d, *J* = 3 Hz), 107.8 (d, *J* = 27 Hz), 72.0, 58.1 (d, *J* = 5 Hz), 47.9, 42.1, 39.4, 23.3; FTIR (ATR): ν 3285, 1731, 1648, 1519 cm⁻¹; HR-MS (ESI) *m/z*: found 322.1571; calculated for C₁₆H₂₁FN₃O₃ [M+H]⁺ 322.1567.



N*-[[*(5S)*]-3-[3-fluoro-4-((2-methoxyethyl)methylamino)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **34*


To a stirred suspension of **23** (50 mg, 0.18 mmol) and K₂CO₃ (50 mg, 0.36 mmol) in DMF (1.0 mL) was added 2-bromoethyl methyl ether (0.15 mL, 1.6 mmol). The mixture was stirred at 80 °C for 3 days, then diluted with CH₂Cl₂ (2 mL), purified by silica gel chromatography (0-3% MeOH/CHCl₃), followed by C18 silica chromatography (5-50% MeCN/H₂O) to yield the title compound **34** as a colourless resin (32 mg, 53%). R_f 0.38 (10%

MeOH/CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ 7.35 (dd, *J* = 14.7, 2.6 Hz, 1H), 7.03 (ddd, *J* = 8.8, 2.6, 0.8 Hz, 1H), 6.89 (dd, *J* = 9.2, 8.8, 1H), 6.34 (t, *J* = 6.1, 1H), 4.76-4.73 (m, 1H), 4.00 (dd, *J* = 9.1, 9.0 Hz, 1H), 3.73 (dd, *J* = 9.1, 6.7 Hz, 1H), 3.68 (ddd, *J* = 14.7, 6.1, 3.2 Hz, 1H), 3.60 (ddd, *J* = 14.7, 6.1, 6.1 Hz, 1H), 3.54 (t, *J* = 5.8 Hz, 2H), 3.34 (s, 3H), 3.31 (t, *J* = 5.8 Hz, 2H), 2.88 (s, 3H), 2.01 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): δ 171.3, 154.8 (d, *J* = 245 Hz), 154.6, 136.7 (d, *J* = 9 Hz), 131.3 (d, *J* = 10 Hz), 119.2 (d, *J* = 5 Hz), 114.2 (d, *J* = 3 Hz), 107.8 (d, *J* = 27 Hz), 72.0, 71.1, 59.0, 54.8 (d, *J* = 5 Hz), 47.9, 42.1, 40.7, 23.2; FTIR (ATR): ν 3287, 1731, 1650, 1519 cm⁻¹; HR-MS (ESI) *m/z*: found 340.1668; calculated for C₁₆H₂₃N₃O₄F [M+H]⁺ 340.1673.




N*-[(5*S*)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-*N*-methylacetamide **9*

To a stirred solution of **1** (30 mg, 0.089 mmol) in DMF (1 mL) under N₂ at 0°C was added NaH (60% in mineral oil, 5 mg, 0.1 mmol), and stirred for 10 min before the addition of methyl iodide (15 mg, 0.11 mmol) in DMF (0.2 mL). The solution was stirred at 0°C for 45 min, then quenched with 1M HCl (0.1 mL), diluted with EtOAc (5 mL), and washed with water (3 x 5 mL). The combined aqueous phases were extracted with EtOAc (2 x 5 mL). The combined organic phases were washed with water (2 x 5 mL), dried (MgSO₄), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-3% MeOH/CH₂Cl₂), to yield the title compound **9** as a white powder (15 mg, 48%). R_f 0.32 (5% MeOH/CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃): δ 7.44 (dd, *J* = 14.3, 2.6 Hz, 1H), 7.08 (ddd, *J* = 8.8, 2.5, 1.0 Hz, 1H), 6.91 (dd, *J* = 9.1, 8.8 Hz, 1H), 4.86-4.82 (m, 1H), 4.01 (dd, *J* = 9.1, 8.9 Hz, 1H), 3.91 (dd, *J* = 14.5, 3.2 Hz, 1H), 3.86-3.85 (m, 4H), 3.74 (dd, *J* = 9.1, 7.0 Hz, 1H), 3.51 (dd, *J* = 14.5, 6.4 Hz, 1H), 3.17 (s, 3H), 3.05-3.03 (m, 4H), 2.11 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): δ 172.5, 155.6 (d, *J* = 246 Hz), 154.4, 136.6 (d, *J* = 9 Hz), 133.2 (d, *J* = 10 Hz), 118.9 (d, *J* = 4 Hz), 114.0 (d, *J* = 3 Hz), 107.6 (d, *J* = 26 Hz), 72.7, 67.1, 51.1 (d, *J* = 3 Hz), 51.0, 48.2, 38.7, 21.9; FTIR (ATR): ν 1722, 1665, 1518 cm⁻¹; HR-MS (ESI) *m/z*: found 352.1667; calculated for C₁₇H₂₂N₃O₄F [M+H]⁺ 352.1673.




N*-[(5*S*)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl}propanamide **5*

The title compound **5** was prepared as by Reddy *et al.*¹ ¹H NMR (500 MHz, CDCl₃): δ 7.42 (dd, *J* = 14.4, 2.6 Hz, 1H), 7.06 (ddd, *J* = 8.9, 2.6, 1.0 Hz, 1H), 6.90 (dd, *J* = 9.1, 8.9 Hz, 1H), 6.24 (t, *J* = 6.0 Hz, 1H), 4.78-4.74 (m, 1H), 4.01 (dd, *J* = 9.1, 9.0 Hz, 1H), 3.86-3.85 (m, 4H), 3.76 (dd, *J* = 9.1, 6.5 Hz, 1H), 3.70-3.61 (m, 2H), 3.05-3.03 (m, 4H), 2.23 (q, *J* = 7.6 Hz, 2H), 1.11 (t, *J* = 7.6 Hz, 3H).



(*S*)-*N*-(3-[3-fluoro-4-morpholinophenyl]-2-oxo-5-oxazolidinyl)methyl}hexanamide **6**


The title compound **6** was prepared as by Reddy *et al.*¹ ¹H NMR (500 MHz, CDCl₃): δ 7.43 (dd, *J* = 14.3, 2.6 Hz, 1H), 7.06 (ddd, *J* = 8.9, 2.6, 1.0 Hz, 1H), 6.90 (dd, *J* = 9.1, 8.9 Hz, 1H), 6.05 (t, *J* = 6.1 Hz, 1H), 4.78-4.74 (m, 1H), 4.01 (dd, *J* = 9.1, 9.0 Hz, 1H), 3.87-3.85 (m, 4H), 3.76 (dd, *J* = 9.1, 6.5 Hz, 1H), 3.71-3.62 (m, 2H), 3.05-3.03 (m, 4H), 2.24-2.14 (m, 2H), 1.57 (tt, *J* = 7.5, 7.5 Hz, 2H), 1.27-1.21 (m, 4H), 0.82 (t, *J* = 7.0 Hz, 3H).



(*S*)-*N*-[[3-[3-Fluoro-4-morpholinophenyl]-2-oxooxazolidin-5-yl]methyl]benzamide **7**

The title compound **7** was prepared as by Reddy *et al.*² ¹H NMR (500 MHz, DMSO-*d*₆): δ 8.82 (t, *J* = 5.7 Hz, 1H), 7.85-7.83 (m, 2H), 7.55-7.52 (m, 1H), 7.50-7.45 (m, 3H), 7.19 (dd, *J* = 8.9, 2.1 Hz, 1H), 7.05 (dd, *J* = 9.3, 8.9 Hz, 1H), 4.88-4.83 (m, 1H), 4.15 (dd, *J* = 9.1, 9.0


Hz, 1H), 3.85 (dd, $J = 9.1, 5.9$ Hz, 1H), 3.73-3.72 (m, 4H), 3.67-3.57 (m, 2H), 2.96-2.94 (m, 4H).




(5S)-5-[(ethylamino)methyl]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone **8**

To a stirred suspension of **4** (75 mg, 0.25 mmol) and K_2CO_3 (27 mg, 0.20 mmol) in acetonitrile (1 mL) was added ethyl bromide (60 mg, 0.55 mmol). The mixture was heated at 60 °C in a sealed tube for 18 h, then concentrated under reduced pressure. The residue was taken up in water (5 mL) and extracted with CH_2Cl_2 (4 x 5 mL), dried ($MgSO_4$), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-10% MeOH/ $CHCl_3$) to yield the title compound **8** as an off-white powder (10 mg, 38%). R_f 0.25 (10% MeOH/ CH_2Cl_2); 1H NMR (400 MHz, $CDCl_3$): δ 7.44 (dd, $J = 14.4, 2.6$ Hz, 1H), 7.13 (ddd, $J = 8.8, 2.6, 1.1$ Hz, 1H), 6.92 (dd, $J = 9.1, 8.8$ Hz, 1H), 4.79-4.72 (m, 1H), 4.00 (dd, $J = 8.6, 8.5$ Hz, 1H), 3.87-3.85 (m, 4H), 3.82 (dd, $J = 8.5, 6.8$ Hz, 1H), 3.05-3.03 (m, 4H), 2.97 (dd, $J = 12.9, 4.4$ Hz, 1H), 2.91 (dd, $J = 12.9, 6.1$ Hz, 1H), 2.75-2.67 (m, 2H), 1.11 (t, $J = 7.1$ Hz, 3H); FTIR (ATR): ν 1733, 1516 cm^{-1} ; HR-MS (ESI) m/z : found 324.1723; calculated for $C_{16}H_{23}N_3O_3F$ $[M+H]^+$ 324.1723.


Preparation of **56**






[3-methoxy-4-(4-morpholinyl)phenyl]carbamic acid benzyl ester **f**

To a stirred solution of 3-methoxy-4-(4-morpholinyl)aniline (1.00 g, 4.82 mmol) in acetone (18 mL) and water (9 mL) was added sodium bicarbonate (0.810 g, 9.64 mmol), and then cooled to 0 °C. Benzyl chloroformate (0.73 mL, 5.1 mmol) was added dropwise, and the mixture was stirred at 0 °C for 1 h, then at r.t. for 1 h, poured into water (30 mL) and stirred for 1 h. The resultant solid was filtered, washed with water (3 x 5 mL) and air dried to yield the title compound **f** as a dark brown powder (1.40 g, 85%). ¹H NMR (400 MHz, CDCl₃): δ 7.42-7.32 (m, 5H), 7.20 (bs, 1H), 6.84 (d, *J* = 8.5 Hz, 1H), 6.74 (dd, *J* = 8.5, 2.3 Hz, 1H), 6.59 (bs, 1H), 5.19 (s, 2H), 3.89-3.86 (m, 7H), 3.02-3.00 (m, 4H).




(5R)-5-(hydroxymethyl)-3-[3-methoxy-4-(4-morpholinyl)phenyl]-2-oxazolidinone **g**

To a stirred solution of **f** (1.40 g, 4.09 mmol) in THF (25 mL) under N₂, cooled to -78 °C, was added dropwise *n*-BuLi (1.6M in hexanes, 3.1 mL, 5.0 mmol). After an additional 30 min, (*R*)-glycidal butyrate (0.69 mL, 4.9 mmol) was added dropwise, and the mixture was allowed to warm to r.t. After 18 h, the mixture was quenched with saturated aqueous NH₄Cl (10 mL), and concentrated under reduced pressure to remove THF, extracted with CH₂Cl₂ (3 x 20 mL), dried (MgSO₄), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-10% MeOH/CHCl₃) then triturated with EtOAc (2 mL) to yield the title compound **g** as an beige powder (592 mg, 47%). R_f 0.38 (10% MeOH/CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ 7.47 (d, *J* = 2.4 Hz, 1H), 6.87 (d, *J* = 8.6 Hz, 1H), 6.75 (dd, *J* = 8.6, 2.4 Hz, 1H), 4.74-4.70 (m, 1H), 4.01 (dd, *J* = 8.8, 8.8 Hz, 1H), 3.98-3.95 (m, 2H), 3.89-3.87 (m, 4H), 3.87 (s, 3H), 3.76-3.73 (m, 1H), 3.03-3.01 (m, 4H), 2.58 (bs, 1H); ¹³C NMR (151 MHz, CDCl₃): δ 155.0, 152.7, 137.9, 134.0, 118.0, 110.3, 103.3, 72.9, 67.3, 63.0, 55.7, 51.3, 46.8; FTIR (ATR): ν 3435, 1727, 1515 cm⁻¹; HR-MS (ESI) *m/z*: found 309.1451 ; calculated for C₁₅H₂₁N₂O₅ [M+H]⁺ 309.1450.




(5R)-5-[[[(methanesulfonyl)oxy]methyl]-3-[3-methoxy-4-(4-morpholinyl)phenyl]-2-oxazolidinone **h**

To a stirred suspension of **g** (500 mg, 1.55 mmol) in CH₂Cl₂ (25 mL) at 0 °C was added triethylamine (0.43 mL, 3.1 mmol), followed by methanesulfonyl chloride (0.15 mL, 1.9 mmol), and the solution was allowed to warm to r.t. After 1 h, the solution was quenched with water (20 mL), and the organic phase was separated, washed with water (20 mL) and brine (10 mL), dried (MgSO₄), filtered and concentrated under reduced pressure to yield presumably the title compound **h** as a brown resin (618 mg) and was used in the next step without further purification.




(5R)-5-(azidomethyl)-3-[3-methoxy-4-(4-morpholinyl)phenyl]-2-oxazolidinone **i**

To a stirred solution of **h** (618 mg) in anhydrous DMF (7 mL) under N₂ was added sodium azide (303 mg, 4.66 mmol) and the mixture was heated at 75 °C. After 3 h, the mixture was cooled to r.t., concentrated under reduced pressure to dryness and taken up in water (20 mL) and EtOAc (10 mL). The aqueous phase was separated and extracted with EtOAc (3 x 5 mL) and the combined organic phases were dried (MgSO₄), filtered and concentrated under reduced pressure, then purified by silica gel chromatography (50-100% EtOAc/hexanes) to yield the title compound **i** as a pale yellow crystalline solid (454 mg, 88% over 2 steps). R_f 0.50 (EtOAc); ¹H NMR (500 MHz, CDCl₃): δ 7.50 (d, *J* = 2.5 Hz, 1H), 6.89 (d, *J* = 8.6 Hz, 1H), 6.72 (dd, *J* = 8.6, 2.5 Hz, 1H), 4.79-4.74 (m, 1H), 4.07 (dd, *J* = 9.0, 8.9 Hz, 1H), 3.89 (s, 3H), 3.89-3.87 (m, 4H), 3.84 (dd, *J* = 9.0, 6.2 Hz, 1H), 3.69 (dd, *J* = 13.2, 4.7 Hz, 1H), 3.58 (dd, *J* = 13.2, 4.5 Hz, 1H), 3.04-3.02 (m, 4H); ¹³C NMR (126 MHz, CDCl₃): δ 154.2, 152.8, 138.1, 133.7, 118.0, 110.1, 103.3, 70.6, 67.3, 55.8, 53.2, 51.3, 47.9; FTIR (ATR): ν 2107, 1733 cm⁻¹; HR-MS (ESI) *m/z*: found 334.1515; calculated for C₁₅H₂₀N₅O₄ [M+H]⁺ 334.1515.



(5*S*)-5-(aminomethyl)-3-[3-methoxy-4-(4-morpholinyl)phenyl]-2-oxazolidinone **j**

To a stirred mixture of **i** (400 mg, 1.2 mmol) in THF (5 mL) and water (0.2 mL) at 0 °C was added trimethylphosphine (1.0 M in toluene, 1.3 mL, 1.3 mmol), then allowed to warm to r.t. After 18 h at r.t., the mixture was concentrated under reduced pressure to remove THF, then diluted with CH₂Cl₂ (5 mL) and water (5 mL), and the organic phase was separated. The aqueous phase was extracted with CH₂Cl₂ (3 x 5 mL), and the organic phases were combined, dried (MgSO₄), filtered and concentrated under reduced pressure, then purified by silica gel chromatography (0-10% MeOH/CH₂Cl₂) to yield the title compound **j** as a colourless resin (226 mg, 61%). *R*_f 0.15 (10% MeOH/CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃): δ 7.52 (d, *J* = 2.5 Hz, 1H), 6.88 (d, *J* = 8.6 Hz, 1H), 6.74 (dd, *J* = 8.6, 2.5 Hz, 1H), 4.67-4.63 (m, 1H), 4.03 (dd, *J* = 8.7, 8.6 Hz, 1H), 3.89 (s, 3H), 3.89-3.87 (m, 4H), 3.83 (dd, *J* = 8.6, 6.7 Hz, 1H), 3.09 (dd, *J* = 13.6, 4.1 Hz, 1H), 3.03-3.02 (m, 4H), 2.98 (dd, *J* = 13.6, 5.9 Hz, 1H); ¹³C NMR (151 MHz, CDCl₃): δ 154.9, 152.8, 137.8, 134.2, 118.0, 110.0, 103.2, 73.9, 67.3, 55.7, 51.4, 48.1, 45.2; FTIR (ATR): ν 3382, 1738, 1511 cm⁻¹; HR-MS (ESI) *m/z*: found 308.1612; calculated for C₁₅H₂₂N₃O₄ [M+H]⁺ 308.1610.




N*-[[[(5*S*)-3-[3-methoxy-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **56*

To a stirred solution of **j** (67 mg, 0.24 mmol) in CH₂Cl₂ (4 mL) was added pyridine (0.02 mL, 0.3 mmol) and acetic anhydride (0.03 mL, 0.3 mmol). After 15 min, the solution was concentrated under reduced pressure and purified by silica gel chromatography (5% MeOH/CHCl₃) to yield the title compound **56**³ as a white powder (57 mg, 75%). *R*_f 0.16 (5% MeOH/CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ 7.45 (d, *J* = 2.5 Hz, 1H), 6.89 (d, *J* = 8.6 Hz, 1H), 6.74 (dd, *J* = 8.6, 2.5 Hz, 1H), 5.97 (bt, 1H), 4.77-4.74 (m, 1H), 4.05 (dd, *J* = 9.1, 9.0 Hz,


1H), 3.89-3.88 (m, 7H), 3.76 (dd, $J = 9.1, 6.8$ Hz, 1H), 3.72 (ddd, $J = 14.7, 6.2, 3.2$ Hz, 1H), 3.59 (ddd, $J = 14.7, 6.2, 6.2$ Hz, 1H), 3.04-3.03 (m, 4H), 2.02 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): δ 171.2, 154.7, 152.7, 138.1, 133.7, 118.0, 110.4, 103.3, 72.0, 67.2, 55.7, 51.3, 48.0, 42.1, 23.2; FTIR (ATR): ν 3286, 1721, 1647, 1519 cm^{-1} ; HR-MS (ESI) m/z : found 350.1721; calculated for $\text{C}_{17}\text{H}_{24}\text{N}_3\text{O}_5$ $[\text{M}+\text{H}]^+$ 350.1716.

Preparation of 57




[4-(3-Oxo-morpholin-4-yl)-phenyl]carbamic acid benzyl ester **a**

The title compound **a** was prepared as by Sturm *et al.*⁴ ^1H NMR (400 MHz, CDCl_3): δ 7.43-7.32 (m, 7H), 7.26-7.23 (m, 2H), 5.20 (s, 2H), 4.32 (s, 2H), 4.02-4.00 (m, 2H), 3.73-3.71 (m, 2H).




4-[4-[(5R)-5-(Hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-morpholinone **b**

The title compound **b** was prepared as by Maraju *et al.*⁵ ¹H NMR (400 MHz, CDCl₃): δ 7.58-7.56 (m, 2H), 7.33-7.31 (m, 2H), 4.72-4.65 (m, 1H), 4.33 (s, 2H), 4.04-3.94 (m, 4H), 3.91-3.88 (m, 1H), 3.75-3.66 (m, 3H), 2.86 (bt, 1H).




4-[4-[(5R)-5-[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-3-morpholinone **c**

The title compound **c** was prepared as by Maraju *et al.*⁵ ¹H NMR (400 MHz, CDCl₃): δ 7.61-7.57 (m, 2H), 7.39-7.35 (m, 2H), 4.96-4.91 (m, 1H), 4.51 (dd, *J* = 11.7, 3.7 Hz, 1H), 4.43 (dd, *J* = 11.7, 4.1 Hz, 1H), 4.34 (s, 2H), 4.17 (dd, *J* = 9.2, 9.1 Hz, 1H), 4.05-4.03 (m, 2H), 3.98 (dd, *J* = 9.2, 6.1 Hz, 1H), 3.77-3.75 (m, 2H), 3.11 (s, 3H).




4-[4-[(5R)-5-(Azidomethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-morpholinone **d**

The title compound **d** was prepared as by Maraju *et al.*⁵ After 3 h of reaction though, the mixture was cooled to r.t., concentrated under reduced pressure to dryness, suspended in water (10 mL) then filtered, washed with water (3 x 5 mL) and air dried to yield the title compound as an off-white powder (787 mg, 71%). ¹H NMR (400 MHz, CDCl₃): δ 7.60-7.58 (m, 2H), 7.37-7.35 (m, 2H), 4.82-4.76 (m, 1H), 4.34 (s, 2H), 4.09 (dd, *J* = 8.9, 8.9 Hz, 1H), 4.05-4.03 (m, 2H), 3.87 (dd, *J* = 8.9, 6.4 Hz, 1H), 3.77-3.74 (m, 2H), 3.71 (dd, *J* = 13.2, 4.5 Hz, 1H), 3.59 (dd, *J* = 13.2, 4.2 Hz, 1H).



4-[4-[(5S)-5-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morpholin-3-one **d**

To a stirred mixture of **d** (765 mg, 2.41 mmol) in THF (10 mL) and water (0.5 mL) at 0 °C was added trimethylphosphine (1.0 M in toluene, 2.8 mL, 2.8 mmol), then allowed to warm to r.t. After 5 h at r.t., the mixture was concentrated under reduced pressure to remove THF, then diluted with CH₂Cl₂ (20 mL) and water (10 mL), and the organic phase was separated. The aqueous phase was extracted with CH₂Cl₂ (2 x 20 mL), and the organic phases were combined, dried (MgSO₄), filtered and concentrated under reduced pressure to yield the title compound **e** as an off-white solid (570 mg, 81%). The NMR data is consistent as that found in the literature.⁶ ¹H NMR (400 MHz, CDCl₃): δ 7.63-7.59 (m, 2H), 7.37-7.33 (m, 2H), 4.72-4.65 (m, 1H), 4.34 (s, 2H), 4.08-4.02 (m, 3H), 3.87 (dd, *J* = 8.6, 6.7 Hz, 1H), 3.77-3.74 (m, 2H), 3.12 (dd, *J* = 13.7, 4.1 Hz, 1H), 2.98 (dd, *J* = 13.7, 5.7 Hz, 1H).



N-[[[(5S)-3-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide **57**

To a stirred solution of **e** (75 mg, 0.26 mmol) in CH₂Cl₂ (5 mL) was added pyridine (0.03 mL, 0.4 mmol) and acetic anhydride (0.03 mL, 0.3 mmol). After 15 min, the solution was concentrated under reduced pressure and purified by silica gel chromatography (0-3% MeOH/CHCl₃) to yield the title compound **57** as a white powder (70 mg, 81%). *R*_f 0.31 (10% MeOH/CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 7.56-7.54 (m, 2H), 7.34-7.32 (m, 2H), 6.43 (bt, 1H), 4.76-4.71 (m, 1H), 4.33 (s, 2H), 4.04-4.00 (m, 3H), 3.78 (dd, *J* = 8.9, 7.0 Hz, 1H), 3.75-3.73 (m, 2H), 3.66-3.62 (m, 1H), 3.60-3.56 (m, 1H), 1.99 (s, 3H). ¹³C NMR (126 MHz, CDCl₃): δ 171.3, 167.0, 154.6, 137.4, 136.8, 126.4, 119.1, 72.0, 68.7, 64.2, 49.8, 47.6, 42.0, 23.2. FTIR (ATR): ν 3290, 1745, 1724, 1647, 1519 cm⁻¹. HR-MS (ESI) *m/z*: found 356.1223; calculated for C₁₆H₁₉N₃O₅Na [M+Na]⁺ 356.1222.

References

1. P. K. Reddy, K. Mukkanti and D. M. Rao, *Orient. J. Chem.*, 2013, **29**, 1015-1019.
2. P. K. Reddy, K. Mukkanti and D. M. Rao, *Asian J. Chem.*, 2012, **24**, 3479-3482.
3. E. Fasani, F. Tilocca, S. Protti, D. Merli and A. Albini, *Org. Biomol. Chem.*, 2008, **6**, 4634-4642.
4. H. Sturm, D. De Souza, K. Knepper and M. Albert, *PCT Intl. Appl.*, 2011, WO2011098501.
5. S. Maroju, P. N. Kumar, R. Maroju, G. Velupula, A. Haq and T. R. Prasad, *J. Applicable Chem.*, 2014, **3**, 2573-2585.
6. C. Li, Y. Liu, Y. Zhang and X. Zhang, *J. Chem.Res.*, 2011, **35**, 400-401.